CLINICAL RESEARCH INTEGRATES WITH GP AND PHARMACIST WORKFLOWS TO SUPPLEMENT PRACTICE REVENUE Primary health introductions to clinical trials leverages community trust in HCPs
With Charlotte Bradshaw,
CEO and Founder Evrima Technologies
SEGMENT
Filmed in Sydney | January 2025
Clinical trials are crucial to the development of evidence-based preventative medicines. In addition, participation in clinical trials can also provide patients with opportunities to access new treatments.
“Clinical trials are at the heart of medical advances which look into new ways to treat, prevent, or detect disease. Volunteers often do so to help contribute to advancing scientific research, knowing that they are participating in the hope of helping future generations,” said Charlotte Bradshaw, CEO and Founder to Evrima Technologies.
Ms Bradshaw spoke to Australian Health Journal about Evrima’s mission. As an Australian-based digital health company bringing trials to patients, GPs and pharmacists, world-class researchers are able to connect to the wider community through primary health care.
There are hundreds of clinical trials happening around the country and they can take place in hospitals, universities, private clinics and dedicated medical research institutes, yet the trusted role of a GP and pharmacists has opportunity to connect the stakeholder groups.
Research reveals that in Australia, 79% of people would consider being involved in a clinical trial, and 69% would be open to hearing about clinical trials from their GP or Health Care Practitioner. However, barriers such as time constraints, workforce shortages and lack of knowledge about the trials have been identified as barriers to GP referrals.
Each year, clinical trials are conducted to investigate treatment strategies (75%), disease prevention (15%), drugs and medicines (45%), and devices, lifestyles, and behaviours.
In Australia, trials that attract higher participation often centre around cancer and cardiovascular disease. Health conditions such as mental health, neurological and musculoskeletal trials, as well as those dealing with everyday issues including asthma and hypertension, often experience lower rates of participation.
With around 80% of clinical trials being delayed due to recruitment issues, Ms Bradshaw says that new referral platforms such as Evrima’s Evripath can simplify the process for practitioners and patients.
“We understand the daily challenges faced by GPs, but also appreciate that GPs are the gatekeepers to patient participation in clinical trials that are working towards better community outcomes,” said Ms Bradshaw.
Note: Research noted above is cited in the segment
-
Child Dental Benefits Schedule needing greater awareness
Since its launch in 2014, the Child Dental Benefits Schedule has seen a gradual increase in participation year on year. The impact of COVID-19 and related shutdowns saw participation fall sharply in 2020. Though it increased 2021, the national target of 41% participation was not reached in 2021-2022, with the total (35.4%) more than three percent below 2018 participation rates.
In an opinion segment, Australian Health Journal spoke with Abano Healthcare Group Clinical Director, Dr Fred Calavassy, with over 30 years of clinical experience, about his observations of the Child Dental Benefits Scheme ways to increasing participation rates.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
